These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 18400125)

  • 1. Assessing short-term effects and costs at an early stage of innovation: the use of positron emission tomography on radiotherapy treatment decision making.
    Remonnay R; Morelle M; Pommier P; Giammarile F; Carrère MO
    Int J Technol Assess Health Care; 2008; 24(2):212-20. PubMed ID: 18400125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Impact of FDG-PET on radiation therapy: economic results of a STIC study].
    Remonnay R; Morelle M; Giammarile F; Pommier P; Carrère MO
    Cancer Radiother; 2009 Jul; 13(4):313-7. PubMed ID: 19493691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis in the clinical management of patients with known or suspected lung cancer: [18F]fluorodeoxyglucose PET and CT comparison.
    Mansueto M; Grimaldi A; Torbica A; Pepe G; Giovacchini G; Messa C; Fazio F
    Q J Nucl Med Mol Imaging; 2007 Sep; 51(3):224-34. PubMed ID: 17538525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of CT and positron emission tomography/CT coregistered images in planning radical radiotherapy in patients with non-small-cell lung cancer.
    Macmanus M; D'Costa I; Everitt S; Andrews J; Ackerly T; Binns D; Lau E; Ball D; Weih L; Hicks RJ
    Australas Radiol; 2007 Aug; 51(4):386-93. PubMed ID: 17635480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is 18F FDG PET-CT cost effective in lung cancer?
    Buscombe J; O'Rourke E
    Expert Rev Anticancer Ther; 2007 Apr; 7(4):471-6. PubMed ID: 17428168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Practical integration of [18F]-FDG-PET and PET-CT in the planning of radiotherapy for non-small cell lung cancer (NSCLC): the technical basis, ICRU-target volumes, problems, perspectives.
    Nestle U; Kremp S; Grosu AL
    Radiother Oncol; 2006 Nov; 81(2):209-25. PubMed ID: 17064802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is FDG PET/CT cost-effective for pre-operation staging of potentially operative non-small cell lung cancer? - From Chinese healthcare system perspective.
    Wang YT; Huang G
    Eur J Radiol; 2012 Aug; 81(8):e903-9. PubMed ID: 22698711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of positron emission tomography for non-small cell lung carcinoma in Canada.
    Sloka JS; Hollett PD; Mathews M
    Med Sci Monit; 2004 May; 10(5):MT73-80. PubMed ID: 15114279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of FDG PET-CT in the management of pulmonary metastases from malignant melanoma.
    Krug B; Crott R; Roch I; Lonneux M; Beguin C; Baurain JF; Pirson AS; Vander Borght T
    Acta Oncol; 2010; 49(2):192-200. PubMed ID: 20059314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of 18F-FDG positron emission tomography and computed tomography in patients with colorectal carcinoma and lymphoma: our initial clinical experience.
    Coha B; Radmilović K; Gardasanić J; Daković M; Stefanić M; Latić A; Mitrecić D
    Acta Clin Croat; 2009 Mar; 48(1):35-9. PubMed ID: 19623870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time trends in nodal volumes and motion during radiotherapy for patients with stage III non-small-cell lung cancer.
    Bosmans G; van Baardwijk A; Dekker A; Ollers M; Wanders S; Boersma L; Lambin P; De Ruysscher D
    Int J Radiat Oncol Biol Phys; 2008 May; 71(1):139-44. PubMed ID: 17996384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 18F-FDG PET in planning radiation treatment of non-small cell lung cancer: where exactly is the tumor?
    Dahele MR; Ung YC
    J Nucl Med; 2007 Aug; 48(8):1402; author reply 1403. PubMed ID: 17673427
    [No Abstract]   [Full Text] [Related]  

  • 13. Integrated fluorine-18 fluorodeoxyglucose (18F-FDG) PET/CT compared to standard contrast-enhanced CT for characterization and staging of pulmonary tumors eligible for surgical resection.
    Quaia E; Tona G; Gelain F; Lubin E; Pizzolato R; Boscolo E; Bussoli L
    Acta Radiol; 2008 Nov; 49(9):995-1004. PubMed ID: 18651256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Noninvasive diagnosis of solitary pulmonary lesions in cancer patients based on 2-fluoro-2-deoxy-D-glucose avidity on positron emission tomography/computed tomography.
    Bar-Shalom R; Kagna O; Israel O; Guralnik L
    Cancer; 2008 Dec; 113(11):3213-21. PubMed ID: 18924145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer.
    De Giorgi U; Valero V; Rohren E; Dawood S; Ueno NT; Miller MC; Doyle GV; Jackson S; Andreopoulou E; Handy BC; Reuben JM; Fritsche HA; Macapinlac HA; Hortobagyi GN; Cristofanilli M
    J Clin Oncol; 2009 Jul; 27(20):3303-11. PubMed ID: 19451443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of FDG-PET/CT in the detection of pancreatic metastases from lung cancer.
    Sato M; Okumura T; Kaito K; Kiyoshima M; Asato Y; Uchiumi K; Iijima H; Hashimoto I; Kaburagi T; Amemiya R
    Ann Nucl Med; 2009 Jan; 23(1):49-57. PubMed ID: 19205838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-induced pneumonitis detected earlier by 18F-FDG-PET than by high-resolution CT: a case report with non-Hodgkin's lymphoma.
    Yamane T; Daimaru O; Ito S; Nagata T; Yoshiya K; Fukaya N; Ito S; Imai T; Uchida H
    Ann Nucl Med; 2008 Oct; 22(8):719-22. PubMed ID: 18982476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic MRI, dynamic multidetector-row computed tomography (MDCT), and coregistered 2-[fluorine-18]-fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET)/CT: comparative study of capability for management of pulmonary nodules.
    Ohno Y; Koyama H; Takenaka D; Nogami M; Maniwa Y; Nishimura Y; Ohbayashi C; Sugimura K
    J Magn Reson Imaging; 2008 Jun; 27(6):1284-95. PubMed ID: 18504748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct costs associated with the disease management of patients with unresectable advanced non-small-cell lung cancer in The Netherlands.
    Pompen M; Gok M; Novák A; van Wuijtswinkel R; Biesma B; Schramel F; Stigt J; Smit H; Postmus P
    Lung Cancer; 2009 Apr; 64(1):110-6. PubMed ID: 18805601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 18F-FDG PET and 18F-FDG PET/CT for assessing response to therapy in esophageal cancer.
    Krause BJ; Herrmann K; Wieder H; zum Büschenfelde CM
    J Nucl Med; 2009 May; 50 Suppl 1():89S-96S. PubMed ID: 19380406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.